PFA the outcome of the Board meeting held on 14.11.25 to consider the unaudited financial results of the company for the quarter and half year ended 30.09.25
Awaiting price reaction for this filing.
The board approved standalone unaudited results for Q2/H1 FY26 on 14 November 2025. The company reported virtually no revenue from operations — total income was just Rs. 0.40 lakh in Q2 (vs Rs. 4.77 lakh in Q1 FY26). It posted a loss of Rs. 22.02 lakh for the quarter and Rs. 44.03 lakh for the half year, with EPS of negative Rs. 0.23. Drug manufacturing operations remain suspended as the FDA licence renewal is pending, and a stalled capital work-in-progress of Rs. 2.65 crore has not been impaired. BSE has suspended normal trading in the scrip due to unpaid listing fees since FY22, now allowing only weekly trade-for-trade settlement. The auditor issued a qualified conclusion flagging missing share certificates for Rs. 53.80 lakh of investments and the stalled capital project, plus an emphasis of matter on the nil revenue.
This is a deeply distressed micro-cap pharma stock with serious going-concern risks — negative reserves of Rs. 1,846.60 lakh, near-zero revenue, suspended BSE trading, and an unresolved FDA licence. Shareholders face material risk of further value erosion; the stock is effectively illiquid and speculative.